• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Peri-procedural anticoagulation in catheter ablation for atrial fibrillation: a review.
Abstract Catheter ablation for rhythm control in atrial fibrillation has been recognized as an established treatment. Patients with atrial fibrillation suffer from an increased risk from thromboembolic events. Long-term stroke risk and mortality has been shown to be reduced after catheter ablation, still the procedure per se is associated with an additive peri-procedural thromboembolic risk. Maintenance of the thrombotic - bleeding equilibrium in such patients during interventional procedures is compelling. Lack of data from randomized studies along with the recent introduction of novel oral anticoagulants in clin...
Source: Current Pharmaceutical Design - December 4, 2016 Category: Drugs & Pharmacology Authors: Vrachatis DA, Giannopoulos G, Kossyvakis C, Vasiliki P, Vavuranakis M, Papaioannou TG, Pagoni S, Pyrgakis VN, Cleman MW, Deftereos SG Tags: Curr Pharm Des Source Type: research

Antiplatelet treatment in stroke: new insights.
CONCLUSIONS: Treatment with an antiplatelet agent is recommended to reduce recurrent stroke and death in patients with a non-cardioembolic ischemic stroke or transient ischemic attack. Moreover, clinicians should carefully assess the pros and cons in each case and individualize the need for prolonged dual antiplatelet therapy. PMID: 27291399 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - June 8, 2016 Category: Drugs & Pharmacology Authors: Milionis H, Liontos A, Vemmos K, Spengos K Tags: Curr Pharm Des Source Type: research

P2Y12 receptor antagonists: which one to choose? A systematic review and meta-analysis.
Conclusion: Newer P2Y12 receptor antagonists are associated with better cardiovascular outcomes in patients with ACS and/or undergoing PCI. Prasugrel use resulted in higher major bleeding rates and no overall mortality benefit compared with clopidogrel. PMID: 27290917 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - June 7, 2016 Category: Drugs & Pharmacology Authors: Briasoulis A, Telila T, Palla M, Siasos G, Tousoulis D Tags: Curr Pharm Des Source Type: research

Dual or single antiplatelet therapy after transcatheter aortic valve implantation? A systematic review and meta-analysis.
CONCLUSION: DAPT compared to SAPT in patients after TAVI increases incidence of hemorrhagic events with no benefits in terms of thrombotic events and cardiovascular mortality. However, these data must be interpreted cautiously and the choice of DAPT over SAPT must be based on an individual patient characteristic according to medical practice criteria. PMID: 27262328 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - May 31, 2016 Category: Drugs & Pharmacology Authors: Raut JS, Karuppayil SM, Gazouli M, Vavuranakis M, Siasos G, Zografos T, Oikonomou E, Vrachatis D, Kalogeras K, Papaioannou T, Kolokathis MA, Moldovan C, Tousoulis D Tags: Curr Pharm Des Source Type: research

Transcatheter Aortic Valve Implantation versus Surgical Aortic Valve Replacement: Meta-Analysis of Clinical Outcomes and Cost-Effectiveness.
Conclusions The present study demonstrated no significant differences in regards to mortality or stroke between the two therapeutic procedures. However, the cost-effectiveness and long-term efficacy of TAVI may require further investigation. Technological improvement and increased experience may broaden the clinical indication for TAVI for low-intermediate risk patients in the future. PMID: 26891807 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - February 19, 2016 Category: Drugs & Pharmacology Authors: Cao C, Liou KP, Pathan FK, Virk S, McMonnies R, Wolfenden H, Indraratna P Tags: Curr Pharm Des Source Type: research

Anticoagulant prevention in patients with atrial fibrillation: alternatives to vitamin K antagonists.
Abstract Patients with nonvalvular atrial fibrillation (AF) and risk factors for stroke need anticoagulation to avoid thromboembolic complications. Vitamin K antagonists (VKAs) are an established pharmacological group the use of which is recommended by guidelines. However, VKAs (like warfarin) have major disadvantages, such as a variable dose-effect relationship, drug and food interactions, the need for regular blood testing and dose titration, and, finally, a substantial risk of bleeding. New oral anticoagulants are intended to replace warfarin, being at least as safe and effective, and lacking some of the disadv...
Source: Current Pharmaceutical Design - December 26, 2012 Category: Drugs & Pharmacology Authors: Kozlowski D, Budrejko S, Raczak G, Rysz J, Banach M Tags: Curr Pharm Des Source Type: research

Clopidogrel, Aspirin and Proton Pump Inhibition after Percutaneous Valve Implants: An Update.
Conclusions: TAVR is a new technology that compresses a tissue valve onto an expandable stent. Technical and procedural issues have been solved, but strokes and major bleeding still affect patients' life despite double antiplatelet therapy given to reduce MACCE. To balance pros and cons, antithrombotic therapy with Warfarin or new anticoagulants can be used in patients with previous AF or NOAF to prevent stroke; while single antiplatelet with PPI is a better alternative in patients with liver disease, gastric ulcer or drug abuse to avoid bleeding events. While waiting for randomized trials, a tailored therapy based upon ph...
Source: Current Pharmaceutical Design - December 4, 2012 Category: Drugs & Pharmacology Authors: Fusari M Tags: Curr Pharm Des Source Type: research

Pages: 1  2